Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease and with complementary mechanisms of action, through partnerships with global pharma companies as well as in-house discovery efforts. With offices in Shanghai and the San Francisco Bay Area, and a highly experienced research and management team, the company has global ambitions and a passion for innovation. Its CEO Dr Weidong Zhong goes back on the reasons why he started Terns Pharmaceuticals, explains the difference the company can make for NASH and cancer patients, and breaks down the challenges of bringing innovative drugs to China.
I felt I could do more and have more impact by building and running a small, nimble and highly efficient organization to discover and develop innovative medicines
